Member Info for Timster

Nah.... It's over bought

Roll on mid summer....

It's because it's run by South Koreans

Great stuff so we will 'soon' have affimers in clinical trials as well as Precision. Another billion dollar opportunity....

It's broken the share price...

And as if by magic....

Great news

https://youtu.be/VwH1OYGgVJM

Middle of the year, 26 mins in

Queue the debate when the middle of the year is on the Smithsonian clock...

From a value to the share holder I'd say the secondary objectives are the most important::
• To characterise the pharmacokinetics (PK) in plasma, urine and tumour of AVA6000, of the preCISION and of active metabolites (doxorubicin and leaving group, ) when given as monotherapy, after a single dose and after multiple dosing. doxorubicinol
• To evaluate the initial antitumour activity of AVA6000 according to RECIST.1.1 criteria (overall response rate [ORR], duration of response [ DoR ], disease control rate [DCR] progression free survival [PFS ] and overall survival

Teams meeting away from the USA.....

RD I suppose you think the mobile telephonic devices and the interweb will catch on?
Only way to do business is jump on that penny farthing and pop round to the neighbours to ink deals over tiffin

Buying in volume!!!

It's too early though, 14.30, booom

Did you get the CEO job ? Or just chief ramp master?

See thread above, "Neil bell in scale space article "

That's tomorrow's RNS, he's bought one of the seized oligarchs houses....
Al loves a Thursday RNS

8.30??

It was reported in the San Jose Mercury News, on a par with the Yorkshire post they say :)

Yeeehaaaaaaa.....

Comparing apples with pears, pointless

There are literally thousands of clinical trials ongoing at the moment. The one we care about is AVA6000

Very different, sng was a new drug.

Avacta is just delivering very well established drugs in a targeted way.

But it's not the data wiggly. It's that RNS the market wants and possibly the large pharma's watching from the sidelines.

We are all invested in avacta and want it to work pretty much everything we read is telling us it's working as you said but that's not good enough for the market or the scientific community